Ganirelix

Pharmacological Actions
Mechanism of Action: Ganirelix is a gonadotropin-releasing hormone (GnRH) antagonist. It can bind to the GnRH receptors on the surface of pituitary cells, rapidly and effectively inhibit the pituitary from secreting gonadotropins, namely follicle-stimulating hormone (FSH) and luteinizing hormone (LH), thereby regulating the hormone levels in the body.
Role in Assisted Reproduction: In assisted reproductive technologies such as in vitro fertilization (IVF), the use of ganirelix can prevent the premature occurrence of the luteinizing hormone (LH) peak, avoid premature luteinization of follicles and ovulation, enable multiple follicles to develop synchronously, so as to obtain more mature eggs and improve the success rate of assisted reproduction.
Clinical Applications
Assisted Reproductive Technology: It is mainly used in the controlled ovarian stimulation protocol and is suitable for women undergoing in vitro fertilization-embryo transfer (IVF-ET) and other assisted reproductive technologies. Generally, it is started to be used during the ovulation induction process when the dominant follicle reaches a certain size or the serum estrogen level reaches a certain degree, so as to prevent premature ovulation and ensure that the egg retrieval surgery can be carried out at an appropriate time to obtain high-quality eggs.
Diseases such as Endometriosis: In some cases, it can also be used to treat gynecological diseases related to hormone levels, such as endometriosis and uterine fibroids. By inhibiting the pituitary from secreting gonadotropins and reducing the estrogen level in the body, it can relieve the symptoms of the diseases and reduce the volume of the lesions.